Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Hormone. University of Paris Sud, Villejuif, France

Survival: 10.2 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: France
City/State/Province: Villejuif
Hospital: University of Paris Sud
Journal: Link
Date: 11/2011

This study involved patients with metastatic castration-resistant prostate cancer who received prior docetaxel-based chemotherapy. The patients were divided into two separate treatment groups. Group A consisted of 49 patients with a median age of 69 years. Group B had 48 patients with a median age of 67 years.

Patients in group A were treated with the chemotherapy agent mitoxantrone and the steroid hormone prednisone.

Group B was treated with mitoxantrone, prednisone, and the biologic therapy agent siltuximab, which is a monoclonal antibody for interleukin-6 (IL-6) and causes inhibition of cancer cell growth.

There were 4 adverse event-related deaths were reported for group A, but they were reported to be due to progressive disease. Grade 3-4 neutropenia, back pain, and pulmonary embolism (blood clot) were also reported.

For group B, there were 9 adverse event-related deaths due to progressive disease, treatment-related pneumonia and cerebral hemorrhage. Grade 3-4 neutropenia, leucopenia, and weakness were also reported.

The median overall survival for group A and group B was 13.0 and 10.2 months, respectively.

This study was supported by Centocor, maker of siltuximab.

Correspondence: Dr. K. Fizazi; email:

E-mail to a Friend Email Physician More Information